News from REMEDY

Can a simple question about work ability say anything about future sickness absence? On November 13, 2026, Mari Nilsen Skinnes will defend her doctoral thesis, Work ability and work participation in rehabilitation, at the University of Oslo.

Most people associate juvenile idiopathic arthritis (JIA) with a disease that affects children and adolescents. But for many, the disease doesn't stop there. New research shows that the consequences can follow patients well into adulthood, affecting both health, quality of life and risk for other diseases.

How can patients with rheumatic diseases receive better and safer treatment? This has been a central question throughout Espen A. Haavardsholm's research career. Now he has been awarded the Gleditsch Prize.

Can an app support patients in their rehabilitation? And can it improve collaboration with therapists?

The researchers have investigated this in the DRIV project.

In this webinar, Kelsey Collins, PhD, presents emerging research into how adipose tissue, hormones and metabolism may influence osteoarthritis, joint damage and pain. This webinar will be available only on 30 October from 8:30 to 9:00 am.

From long hospital stays and careful escalation of medications to early targeted treatment, less stressful treatment for children and new studies on hand osteoarthritis. At the Dialogue Seminar 2026, patients, researchers and practitioners met to talk about where rheumatology stands today – and what might be next.

The title of the PhD thesis is Treatment effectiveness, health-related quality of life and long-term outcomes in adults with juvenile idiopathic arthritis

A new Norwegian study estimates that 60 percent vaccine uptake could result in 2,550 fewer cases of shingles per 10,000 people with rheumatoid arthritis after the age of 50. It also estimates 1,303 fewer cases of long-term nerve pain. The vaccine is not publicly covered.

Getting a scientific article published is just the first step. For research to have any impact, someone has to read it, understand it, trust the results, and use the knowledge. That was the main message when Professor and Journal Editor Michael Bretthauer met with the researchers in REMEDY, when WP1 invited them to a seminar.

When researchers, therapists and patients meet, new knowledge can become both more relevant and easier to understand. On Tuesday, September 22, 2026, the Norwegian Rheumatology Association, Diakonhjemmet Hospital and the REMEDY research center invite you to the annual free event, the Dialogue Seminar.

A large study of almost 39,000 patients shows clear differences between European countries. In wealthier countries, patients started treatment earlier – but also switched more quickly.

Digital treatment tools can be developed, validated and researched without being made available to patients. During Arendal Week, participants pointed out obstacles related to regulations, procurement, financing, legal assessments and the responsibility for achieving national dissemination.